FDA Puts Hold on CTI-1601 Clinical Development

FDA Puts Hold on CTI-1601 Clinical Development

295269

FDA Puts Hold on CTI-1601 Clinical Development

The U.S. Food and Drug Administration has put a hold on the clinical development of CTI-1601, an investigational treatment for Friedreich’s ataxia (FA) that is being developed by Larimar Therapeutics. According to a press release from Larimar, the hold was put in place after Larimar notified the FDA of deaths that occurred at the highest dose levels in an ongoing 180-day toxicology study being conducted in non-human primates (NHPs, usually macaques or other species of…

You must be logged in to read/download the full post.